Whether you work in R&D, Clinical Trials, Submissions, Marketing, Distribution, or Regulatory Affairs, effective medical writing is a must -- particularly when even the smallest of errors can disrupt the product lifecycle. That's why all industry professionals – regardless of role or level – should attend this informative webinar for a back-to-basics overview of "Medical Writing 101."
As the FDA faces the implementation of new user fee programs, defining evidence standards will solidify the FDA's role in pre- and post-approval evidence generation. How the FDA interprets its evolving authority will have a direct impact on patient access to innovative medical technologies.
Join us for a complimentary webinar on Tuesday, June 5th 10 a.m. PDT to learn how leading Pharma companies such as Allergan, J&J and BMS are leveraging a new generation of cloud-based, domain-specific sales and marketing analytics for superior market insight and action.
New Rules From FDA: In a new guidance document, FDA lays groundwork for testing new drugs in early stage, high-risk breast cancer and securing approval with just one pivotal trial. Guidance could dramatically shorten time for drug development.